[123] confirm these observations: among the 36/417 patients receiving targeted treatment, 19% were treated successfully with a PFS2/PFS1 ratio > 1.3, including three objective responses, again mainly driven by dabrafenib/trametinib in BRAF V600E‐altered GBM and erdafitinib in FGFR3‐altered GBM, while the median PFS was 2.1 months. This evidence concerns the gene BRAF and glioblastoma.